説明
Primary and secondary outcome measures for evaluating probiotic efficacy in reducing enteral nutrition-related gastrointestinal side effects are defined.
Figure 4
Source Paper
The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition - study protocol for a …Cite This Figure
![Figure 4: Primary and secondary outcome measures for evaluating probiotic efficacy in reducing enteral nutrition-related gastrointestinal side effects are defined.]() > Source: Karolina Kaźmierczak-Siedlecka et al. "The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving ." *Nutrition journal*, 2020. PMID: [32917221](https://pubmed.ncbi.nlm.nih.gov/32917221/)
<figure> <img src="" alt="Primary and secondary outcome measures for evaluating probiotic efficacy in reducing enteral nutrition-related gastrointestinal side effects are defined." /> <figcaption>Figure 4. Primary and secondary outcome measures for evaluating probiotic efficacy in reducing enteral nutrition-related gastrointestinal side effects are defined.<br> Source: Karolina Kaźmierczak-Siedlecka et al. "The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving ." <em>Nutrition journal</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32917221/">32917221</a></figcaption> </figure>